📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
36 announcements match the current filters (relevance ≥ 5).
Viyash Scientific Appoints Carlyle Leaders to Board and Revises ESOP Pool to 1.31 Crore Options
Viyash Scientific Limited has appointed Amit Jain and Abhiroop Jayanthi, both senior representatives from the Carlyle Group, to its Board of Directors as Non-Executive Directors. This strategic move brings significant private equity and industry expertise from a global investment firm to the company's leadership. Additionally, the Board approved a downward revision of the ESOP 2026 pool from 1,34,75,000 to 1,30,98,000 stock options. These appointments are subject to shareholder approval and signify strong institutional oversight and backing.
Key Highlights
Appointment of Amit Jain (Head of Carlyle India) and Abhiroop Jayanthi (MD at Carlyle) as Additional Directors.
Revision of ESOP 2026 pool to 1,30,98,000 options, a reduction of 3,77,000 options from the previous proposal.
New directors bring extensive experience in healthcare, life sciences, and private equity sectors.
Board meeting concluded within approximately one hour (11:30 AM to 12:39 PM) on April 22, 2026.
👀 What to Watch
Investors should view the inclusion of Carlyle leadership as a positive sign for corporate governance and strategic growth. Monitor how this institutional expertise influences future capital allocation and expansion plans.
Viyash Scientific Shareholders Approve MD Appointment and Significant ESOP Grant
Shareholders of Viyash Scientific Limited have approved the appointment of Dr. Haribabu Bodepudi as Managing Director and Group CEO for a two-year term with a 97.32% majority. The company also received approval to grant stock options exceeding 1% of the issued capital to a specific identified employee, supported by 97.31% of votes. Additionally, the appointments of Mr. Rajaram Narayanan and Mr. Srinivas Vasireddy as Whole-time Directors were cleared with over 98% favor. These results ensure management stability and provide tools for key personnel retention following the company's rebranding.
Key Highlights
Dr. Haribabu Bodepudi confirmed as MD & Group CEO for 2 years with 97.32% votes in favor
Special resolution passed to grant ESOPs exceeding 1% of issued capital to a single employee
Mr. Rajaram Narayanan and Mr. Srinivas Vasireddy appointed as Whole-time Directors with 98.83% and 98.64% support respectively
Total voting turnout ranged between 74.8% and 79.3% of outstanding shares across different resolutions
👀 What to Watch
Investors should take confidence in the high level of shareholder support for the new leadership team. Monitor the company's operational performance under the newly confirmed CEO to validate the long-term growth strategy.
Viyash Scientific Proposes New MD & CEO and ESOP Grant Exceeding 1% Capital
Viyash Scientific Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Dr. Haribabu Bodepudi as Managing Director and Group CEO for a two-year term. A key resolution includes the grant of stock options to Dr. Bodepudi exceeding 1% of the company's issued capital within a single year under the ESOP Scheme 2026. The company is also seeking approval for the appointments of Mr. Rajaram Narayanan and Mr. Srinivas Vasireddy as Whole-time Directors. The e-voting process for these special resolutions will conclude on March 12, 2026.
Key Highlights
Appointment of Dr. Haribabu Bodepudi as MD and Group CEO for a 2-year tenure effective Dec 16, 2025
Proposal to grant ESOPs exceeding 1% of total issued capital to the CEO in a single year
Appointment of Mr. Rajaram Narayanan and Mr. Srinivas Vasireddy as Whole-time Directors
Remote e-voting period scheduled from February 11, 2026, to March 12, 2026
Results of the postal ballot to be announced on or before March 16, 2026
👀 What to Watch
Investors should monitor the voting results to see if the significant ESOP grant is approved, as it indicates potential equity dilution. Evaluate the new leadership's ability to drive growth following the company's rebranding from Sequent Scientific.
Viyash Scientific Q3 FY26 Revenue Up 11% to ₹858 Cr; Adjusted EBITDA Surges 64%
Viyash Scientific reported a robust performance for Q3 FY26, with revenue growing 11% YoY to ₹858 crores and adjusted EBITDA rising 64% to ₹185 crores. The company achieved a significant margin expansion of 390 basis points to 21%, driven by vertical integration and operational efficiencies. Despite one-time merger-related exceptional costs of approximately ₹49 crores, the balance sheet strengthened as net debt-to-EBITDA fell below 4x. Management is now pivoting toward high-growth segments like companion animals and CDMO services.
Key Highlights
Revenue for Q3 FY26 stood at ₹858 crores, up 11% YoY, while 9-month revenue reached ₹2,500 crores.
Adjusted EBITDA grew 64% YoY to ₹185 crores with a healthy margin of 21%.
Net debt-to-EBITDA leverage improved significantly to less than 4x compared to the previous year.
Incurred one-time exceptional items of ₹41 crores for merger execution and ₹7.7 crores for tax regime transitions.
Signed an exclusive distribution agreement with Boehringer Ingelheim to expand the companion animal business in India.
👀 What to Watch
Investors should take note of the significant margin improvement and successful debt reduction following the SeQuent-Viyash merger. The stock remains a watch for long-term growth as the company scales its high-margin companion animal and CDMO verticals.
Viyash Scientific Q3 FY26 EBITDA Jumps 64% YoY; Margins Expand to 21.6% on Merger Synergies
Viyash Scientific reported a strong Q3 FY26 with consolidated revenue growing 11% YoY to ₹8,584 million. The company's EBITDA saw a significant jump of 64% YoY to ₹1,854 million, driven by a 690 bps margin expansion to 21.6%. Net debt levels improved substantially, with the Net Debt to LTM EBITDA ratio falling to 0.4x from 1.2x a year ago. This quarter marks the first time results are announced for the merged entity, showcasing early benefits from R&D and manufacturing synergies.
Key Highlights
Consolidated revenue reached ₹8,584 million in Q3 FY26, an 11% YoY increase.
EBITDA surged 64% YoY to ₹1,854 million, with margins improving to 21.6% from 14.6%.
Net Debt to LTM EBITDA ratio improved to 0.4x, down from 1.2x in Q3 FY25.
Formulations segment grew 20% YoY to ₹4,809 million, while API business grew 3% to ₹3,658 million.
Exceptional costs of ₹413 million were incurred due to merger-related stamp duty and professional fees.
👀 What to Watch
The significant margin expansion and debt reduction post-merger signal strong operational efficiency and synergy realization. Investors should monitor the company's ability to maintain these margins as it scales its CDMO and companion animal portfolios.
Viyash Scientific Q3 FY26 Revenue up 11% to ₹8,584 Mn; EBITDA Jumps 64% Post-Merger
Viyash Scientific reported a strong Q3 FY26 performance, the first quarter since its merger, with consolidated revenue growing 10.9% YoY to ₹8,584 million. EBITDA surged 64.4% to ₹1,854 million, with margins expanding significantly from 14.6% to 21.6% due to cost synergies and new product launches. Although Q3 PAT growth was moderated to 15.5% at ₹485 million due to ₹413 million in one-time merger costs, the 9-month PAT grew an impressive 230% YoY. The company has strengthened its balance sheet, reducing its Net Debt/EBITDA ratio to a healthy 0.38x.
Key Highlights
Q3 FY26 Revenue grew 10.9% YoY to ₹8,584 million with 9-month revenue up 11.9% at ₹25,004 million
EBITDA for Q3 increased 64.4% YoY to ₹1,854 million, reflecting a margin of 21.6%
9-month FY26 PAT surged 230% YoY to ₹1,583 million despite exceptional merger-related costs
Net Debt/EBITDA ratio improved to 0.38x following the pre-closure of high-cost debt
Management announced a strategic shift towards Companion animal portfolio and CDMO services
👀 What to Watch
The strong margin expansion and debt reduction post-merger indicate successful integration and operational efficiency. Investors should maintain a positive outlook while monitoring the execution of the new CDMO and companion animal growth strategies.
Viyash Scientific Reports Q3 Revenue of ₹8,584M and Announces Key Management Changes
Viyash Scientific Limited (formerly Sequent Scientific) reported a consolidated revenue of ₹8,584 million for Q3 FY26, showing steady growth from ₹8,503 million in the previous quarter. The company has restructured its senior management team, appointing new VPs for R&D and Quality to align with post-merger strategic objectives. Net profit for the quarter stood at ₹485.20 million, which was significantly impacted by one-time merger-related exceptional expenses of ₹412.60 million. The board also approved a new 2026 ESOP scheme to incentivize leadership following the successful amalgamation of multiple entities.
Key Highlights
Consolidated revenue for Q3 FY26 reached ₹8,584 million compared to ₹8,503 million in Q2 FY26.
Profit After Tax (PAT) stood at ₹485.20 million, affected by ₹412.60 million in exceptional merger costs.
Appointed three new Senior Management Personnel (SMP) in R&D, Quality, and COO roles for subsidiaries.
Completed the allotment of 18.19 crore equity shares as part of the composite scheme of amalgamation.
Approved the 'Viyash Scientific Limited Employee Stock Option Scheme 2026' for eligible employees.
👀 What to Watch
Investors should monitor the operational efficiency of the newly merged entity and the impact of the leadership changes on R&D output. The current financials are heavily influenced by one-time merger costs, so core EBITDA margins in upcoming quarters will be the key metric to watch.
Viyash Scientific Q3 PAT at ₹485.2M; Completes Major Merger and Restates Financials
Viyash Scientific reported a consolidated revenue of ₹8,584 million for Q3 FY26, showing steady growth from ₹7,740.3 million in the restated previous year quarter. The company successfully completed its massive Composite Scheme of Amalgamation, leading to a restatement of historical financials to reflect the merged entity. Net profit for the quarter stood at ₹485.2 million, which was impacted by one-time exceptional merger-related expenses of ₹412.6 million. The board also approved a new ESOP scheme and restructured senior management to align with post-merger strategic objectives.
Key Highlights
Revenue from operations grew to ₹8,584 million in Q3 FY26 compared to ₹7,740.3 million in Q3 FY25 (restated).
Net Profit for Q3 FY26 reached ₹485.2 million, despite ₹412.6 million in exceptional merger-related costs.
Issued 18.19 crore equity shares and 2.03 crore warrants as part of the amalgamation share exchange.
9M FY26 consolidated revenue reached ₹25,003.5 million with a total PAT of ₹1,582.7 million.
Introduced 'Viyash Scientific Limited ESOP Scheme 2026' and appointed new VPs for R&D and Quality.
👀 What to Watch
Investors should focus on the company's ability to drive operational synergies following the completion of the large-scale merger. The restated financials provide a new baseline for performance, and the management restructuring suggests a shift toward aggressive growth in the API and Animal Health segments.
Viyash Scientific Q3 Revenue Rises 11% to ₹8,584 Million Post-Merger Integration
Viyash Scientific (formerly Sequent Scientific) reported a consolidated revenue of ₹8,584 million for Q3 FY26, an 11% increase over the restated ₹7,740.30 million in the same period last year. Net profit for the quarter stood at ₹485.20 million, up from ₹419.40 million YoY, despite incurring ₹412.60 million in exceptional expenses related to its massive amalgamation scheme. The company has successfully integrated multiple entities including Viyash Life Sciences and Symed Labs, leading to a significant restatement of historical financials to reflect the new corporate structure. The board also approved a new ESOP scheme and key senior management appointments to drive post-merger synergies.
Key Highlights
Revenue from operations grew 10.9% YoY to ₹8,584 million in Q3 FY26.
Consolidated Profit After Tax (PAT) reached ₹485.20 million compared to a restated ₹419.40 million in Q3 FY25.
Exceptional items of ₹412.60 million were recognized during the quarter for amalgamation-related expenses.
The company allotted 18.19 crore equity shares and 2.03 crore warrants as part of the merger share exchange.
New Senior Management Personnel appointed in R&D, Quality, and Regulatory roles to align with post-merger strategic objectives.
👀 What to Watch
Investors should view the successful completion of the complex merger as a significant scale-up event that transforms the company's asset base. Monitor the next two quarters for margin expansion as operational synergies from the integrated entities begin to reflect in the bottom line.
Viyash Scientific Partners with Boehringer Ingelheim for India Companion Animal Portfolio
Viyash Scientific's subsidiary, Alivira Animal Health, has entered a strategic partnership with Boehringer Ingelheim India to distribute and promote their companion animal products. This collaboration aims to leverage Alivira's extensive distribution network across urban and rural India to capture the growing pet healthcare market. The announcement follows the recent completion of the merger and name change from Sequent Scientific to Viyash Scientific on January 8, 2026. This move strengthens Viyash's position in the high-margin companion animal segment by adding a global leader's innovative product pipeline to its portfolio.
Key Highlights
Alivira Animal Health to distribute and promote Boehringer Ingelheim's companion animal portfolio in India
Viyash Scientific is currently ranked among the top 25 animal health companies globally, serving over 100 countries
Partnership targets the rapidly growing Indian pet healthcare market driven by rising ownership and preventive care awareness
The company officially transitioned from Sequent Scientific to Viyash Scientific on January 8, 2026, following a merger
Viyash employs over 3,000 people and maintains manufacturing and R&D operations across India, Spain, Brazil, Turkey, and the USA
👀 What to Watch
Investors should monitor the revenue contribution from this partnership as it scales Viyash's domestic formulation business. The association with a global giant like Boehringer Ingelheim validates Viyash's distribution capabilities and enhances its strategic positioning in the animal health sector.
Viyash Scientific Announces CRISIL Rating Withdrawal for Symed Labs Post-Amalgamation
Viyash Scientific Limited (formerly Sequent Scientific) has announced that CRISIL has withdrawn the credit ratings for Symed Labs Ltd following its successful amalgamation into the parent group. Symed Labs, which reported a revenue of ₹785 crore and a PAT of ₹120 crore in FY25, has ceased to exist as a separate legal entity. The withdrawn ratings include 'CRISIL A/Watch Developing' and 'CRISIL A1' for bank facilities totaling approximately ₹182 crore. This withdrawal is a standard procedural step following the merger effective as of December 2025.
Key Highlights
Symed Labs amalgamated with Viyash Lifesciences and subsequently with Sequent Scientific (now Viyash Scientific) in late 2025
CRISIL withdrew ratings for ₹162 crore fund-based and ₹20 crore non-fund-based facilities at the company's request
Symed Labs reported strong FY25 financials with a PAT margin of 15.4% and revenue growth to ₹785 crore
The entity maintained a very healthy capital structure with an adjusted debt/networth ratio of 0.03 times
Viyash Scientific is a Carlyle-backed pharmaceutical player with a global footprint in API and animal health
👀 What to Watch
This is a routine administrative update following a corporate restructuring; investors should focus on the consolidated financial performance of the merged Viyash Scientific entity. No change in the underlying credit strength is implied by this procedural withdrawal.
Sequent Scientific Shareholders Approve Name Change to Viyash Scientific with 99.99% Majority
Shareholders of Sequent Scientific Limited have overwhelmingly approved a special resolution to change the company's name to Viyash Scientific Limited. The proposal received 99.99% approval, with 174.26 million votes in favor and only 17,224 against. Additionally, shareholders approved the alteration of the company's Objects Clause in the Memorandum of Association. This rebranding follows the company's integration into the Viyash platform and marks a significant shift in corporate identity.
Key Highlights
Special resolution for name change to Viyash Scientific Limited passed with 99.99% of valid votes.
Alteration of the Objects Clause in the Memorandum of Association approved by 99.99% of voting shareholders.
Promoter group showed 100% support for the resolutions, casting 131.68 million votes in favor.
Public institutions also showed strong support with 89.98% participation and 100% votes in favor.
The resolutions are deemed passed as of December 28, 2025, following the conclusion of the postal ballot.
👀 What to Watch
Investors should note the upcoming change in company name and potential ticker symbol update on BSE and NSE. While the rebranding reflects a new corporate phase, investors should continue to monitor the company's operational performance under the new identity.
CA Hull Investments Acquires 31.2% Stake in Sequent Scientific via Viyash Merger
Sequent Scientific has completed the allotment of equity shares following its composite scheme of amalgamation with Viyash Life Sciences and other entities. CA Hull Investments was allotted 13,61,60,231 shares, representing a 31.20% stake in the post-merger entity. This transaction brings the total promoter group holding, including CA Harbor Investments, to 61.4%. The allotment was executed based on a swap ratio of 56 Sequent shares for every 100 Viyash shares as approved by the NCLT.
Key Highlights
Allotment of 13,61,60,231 equity shares to CA Hull Investments following the Viyash merger.
CA Hull Investments now holds a 31.20% stake in Sequent Scientific.
Total promoter group holding increased to 61.4% in the expanded equity base.
Share exchange ratio set at 56 Sequent shares (FV ₹2) for every 100 Viyash shares (FV ₹10).
The merger was sanctioned by the NCLT Hyderabad bench vide order dated November 18, 2025.
👀 What to Watch
Investors should view the completion of this merger as a significant scale-up event for Sequent Scientific. Monitor upcoming quarterly results for operational synergies and the impact of Viyash's integration on the consolidated bottom line.
Sequent Scientific Completes Viyash Merger; Allots 18.19 Cr Shares and 2.03 Cr Warrants
Sequent Scientific has finalized its composite scheme of amalgamation, effectively merging Viyash Life Sciences and several other entities into the company. As part of the deal, Sequent allotted 18.19 crore new equity shares to Viyash shareholders at a swap ratio of 56:100, increasing the total paid-up capital to Rs 87.21 crore. The company also issued 2.03 crore share warrants at Rs 181.94 each, receiving an upfront payment of Rs 92.52 crore. A significant leadership change accompanies the merger, with industry veteran Dr. Haribabu Bodepudi appointed as the new Managing Director and Group CEO.
Key Highlights
Allotment of 18,19,21,827 equity shares to Viyash shareholders at a ratio of 56 Sequent shares for every 100 Viyash shares.
Total paid-up equity capital increased from Rs 50.82 crore to Rs 87.21 crore, representing a ~71.6% expansion.
Issuance of 2.03 crore share warrants at Rs 181.94 per warrant, with Rs 92.52 crore (25%) received upfront.
Appointment of Dr. Haribabu Bodepudi (former Mylan India CEO) as MD and Group CEO for a 2-year term.
CA Hull Investments officially inducted as a promoter, and Appco Pharma LLC becomes a material subsidiary.
👀 What to Watch
Investors should view this as a transformative growth move that expands Sequent's scale and leadership depth, though they must factor in the significant equity dilution. Monitor the integration of Viyash's API and formulation assets for realized synergies in upcoming quarterly results.
Sequent Scientific Allots 18.19 Cr Shares for Viyash Merger; Appoints New MD & Group CEO
Sequent Scientific has completed a major milestone in its merger with Viyash Life Sciences, allotting 18.19 crore equity shares to Viyash shareholders at a 56:100 ratio. This move increases the company's paid-up equity capital from ₹50.82 crore to ₹87.21 crore. Additionally, the board approved the allotment of 2.03 crore share warrants at ₹181.94 each, raising ₹92.52 crore upfront. A significant leadership change sees Dr. Haribabu Bodepudi, former Global COO of Mylan, taking over as Managing Director and Group CEO to drive the integrated entity.
Key Highlights
Allotment of 18,19,21,827 equity shares to Viyash shareholders, expanding total shares to 43.60 crore.
Issuance of 2,03,41,257 share warrants at ₹181.94 per warrant, with 25% upfront payment received.
Appointment of Dr. Haribabu Bodepudi as MD and Group CEO for a 2-year term starting Dec 16, 2025.
CA Hull Investments officially inducted as a promoter of the company following the merger.
Authorized share capital significantly increased to ₹886.15 crore to accommodate the new capital structure.
👀 What to Watch
Investors should recognize this as a transformative scale-up that combines Sequent's animal health strengths with Viyash's API capabilities under high-caliber global leadership. The stock may see re-rating as the market prices in the synergies and the expertise of the new CEO.
Sequent Scientific Allots 18.19 Cr Shares for Viyash Merger; Appoints New MD & Group CEO
Sequent Scientific has finalized its mega-merger with Viyash Life Sciences and several other entities, effective December 16, 2025. The company approved the allotment of 18.19 crore equity shares to Viyash shareholders at a ratio of 56:100, which will increase the total paid-up capital from Rs 50.82 crore to Rs 87.21 crore. Additionally, 2.03 crore share warrants were issued at Rs 181.94 each, with an upfront payment of Rs 92.52 crore already received. The board also appointed Dr. Haribabu Bodepudi as the new Managing Director and Group CEO to lead the combined entity.
Key Highlights
Allotment of 18,19,21,827 equity shares to Viyash shareholders at a swap ratio of 56:100.
Paid-up equity share capital increased by approximately 71.6% to Rs 87.21 crore.
Issuance of 2,03,41,257 share warrants at Rs 181.94 per warrant, raising Rs 92.52 crore as 25% upfront payment.
Appointment of Dr. Haribabu Bodepudi as MD and Group CEO for a 2-year term starting December 16, 2025.
CA Hull Investments officially classified as a promoter following the effectiveness of the scheme.
👀 What to Watch
Investors should view this as a transformative scale-up that consolidates multiple life sciences businesses under one roof. Monitor the integration of Viyash's assets and the strategic direction under the new leadership of Dr. Bodepudi.
